Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel Clears Solasia’s PTCL Drug for Approval
May 13, 2022
- Japan Confirms 1st Cases of BA.4, BA.5 Omicron Subvariants
May 13, 2022
- Japan Enacts Economic Security Law; Supply Chain Clauses to Take Effect in 9 Months after Promulgation
May 12, 2022
- Side Effects after Drug Switches Up for MHLW Panel Review: Minister
May 11, 2022
- Xevudy’s Reduced Efficacy against BA.2 Cited in Updated COVID Guide
May 11, 2022
- PMDA Publishes 1st Example of GMP Shortfalls; Failure to Check Name of Raw Material Supplier
May 10, 2022
- Solasia’s PTCL Med, Rinvoq and Adcetris Label Expansions Up for PAFSC Review on May 12
May 9, 2022
- Maruho’s Rozex in Line for Rosacea Nod in Japan
May 9, 2022
- Probable Cases of Mysterious Pediatric Hepatitis Now Increased to 7 in Japan
May 9, 2022
- Japan Panel OKs Second Booster for Age 60-Plus, and High-Risk Adults
April 28, 2022
- Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
April 28, 2022
- Products Filed for Conditional OK Can Be Switched to Emergency Approval: MHLW Official
April 27, 2022
- Japan Panel OKs Comirnaty, Spikevax for 4th Shot, Use Limited to High-Risk People
April 26, 2022
- SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
- MHLW to Further Bankroll Shionogi’s COVID-19 Pill, Kowa’s Ivermectin
April 25, 2022
- Japan to Raise Pharmacy Stock Levels for Lagevrio, Paxlovid
April 25, 2022
- Upper House Starts Deliberations on PMD Law Amendment Bill
April 25, 2022
- Single-Year Comparison of PMP and Deferred Price Cuts Not Appropriate: Health Minister
April 22, 2022
- Comirnaty, Spikevax for PAFSC Review on April 25; HSC to Discuss 4th Shot on April 27
April 22, 2022
- LDP Adopts Proposal on 4th COVID-19 Vaccination, Urges Govt to Ponder Cost-Effectiveness
April 20, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…